Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Single Arm Study of IMC-1121B in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy

NCT00515697 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00515697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00515697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Single Arm Study of IMC-1121B in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2007
Completion date
May 31, 2011
Enrollment
39 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma